OrCam Technologies

Israel · www.orcam.com · 11 vendors

OrCam Technologies develops and manufactures AI-powered assistive technology devices for individuals who are visually impaired, blind, or have reading challenges. Their products, such as OrCam MyEye and OrCam Read, use computer vision and machine learning to provide audio feedback, allowing users to read text, recognize faces, and identify products, fostering independence and improving quality of life.

Resilience scores

Technology vendors

Services catalogue

2 services in catalogue across 2 categories; runs on 11 sub-vendors.

Insights

Last updated 2026-08-15 · revision 1

11 direct vendors, 181 subvendors

Direct vendors by controlling owner country (sample)

Subvendors by controlling owner country (sample)

Migration Readiness: 5/10

Assessed by AI based on technology stack characteristics (cloud-native vs legacy, containerization, microservices), regulatory environment, data residency requirements, financial stability, and vendor lock-in risks. The score ranges from 0-10, where higher scores indicate better readiness for technology migration.

OrCam Technologies exhibits a medium level of migration readiness, scoring 45 out of 100. The primary challenge stems from its architectural reliance on "On-device Embedded AI / Edge Computing" for core functionalities. While this design offers performance and privacy benefits, it implies that a significant portion of their technology is not inherently cloud-native, containerized, or microservices-based. A full migration to a cloud-centric model would likely necessitate substantial re-architecture or a complex hybrid approach, increasing the effort and cost involved. A major impediment to assessing readiness is the explicit "Unknown" vendor lock-in risk. The ambiguity in vendor data (stating "Total Vendors: 0" yet listing "Total Services: 13" with vendor countries) further complicates understanding potential dependencies and the ease of disentanglement during a migration. Additionally, critical information regarding financial stability (which impacts the ability to fund a migration), specific regulatory compliance requirements, and data residency requirements is not provided. These unknowns introduce considerable risk and complexity to any migration planning. On the positive side, the use of Android and iOS for companion mobile apps suggests existing cloud backend components that would likely be amenable to standard cloud migration strategies. Furthermore, the company utilizes existing cloud-based SaaS solutions like Helpjuice and Google Tag Manager, indicating some familiarity with external cloud services, though these are not core product technologies.

Compliance

10 in-scope frameworks identified; showing 3.

EU Medical Device Regulation — Assessment Required

Risk is Medium because: (1) OrCam's devices assist users with medical conditions (visual impairment, low vision, blindness) and may meet the definition of a medical device under EU MDR or FDA regulations depending on their intended purpose and claims; (2) if OrCam's devices are classified as medical devices, they must comply with EU MDR (CE marking, clinical evaluation, post-market surveillance, UDI) and/or FDA 510(k) clearance or De Novo classification; (3) OrCam's website explicitly states 'OrCam is not a medical organization and this website is not designed to provide diagnosis or medical advice,' suggesting the company positions its products as consumer/assistive technology rather than medical devices; (4) however, the line between assistive technology and medical devices is increasingly scrutinized by regulators; (5) if not classified as medical devices, EU MDR and FDA medical device regulations would not apply, but this classification itself requires regulatory assessment; (6) risk is Medium because misclassification could result in market withdrawal, significant fines, and reputational damage.

Evidence: https://www.orcam.com/en-us/terms-of-use, https://www.orcam.com/en-us/home

EU AI Act (source) — Assessment Required

Risk is High because: (1) OrCam's core products are AI-powered systems that perform real-time image recognition, face recognition, text reading, and object identification — these are AI systems as defined under the EU AI Act; (2) face recognition and biometric identification capabilities in OrCam's devices (MyEye products) may classify as 'high-risk AI systems' under Annex III of the EU AI Act, particularly under categories related to biometric identification and categorization of natural persons; (3) the EU AI Act prohibits certain real-time remote biometric identification systems in public spaces (with exceptions), and OrCam's wearable face recognition capability requires careful legal analysis; (4) OrCam sells products in EU member states through OrCam GmbH (Germany) and distributors, making it subject to EU AI Act obligations as a 'provider' of AI systems placed on the EU market; (5) high-risk AI system obligations include: conformity assessment, technical documentation, EU declaration of conformity, CE marking, registration in EU database, post-market monitoring, and transparency requirements; (6) the EU AI Act entered into force August 2024 with phased implementation (prohibited practices: February 2025; high-risk systems: August 2026); (7) non-compliance penalties reach €30M or 6% of global annual turnover. The risk is High due to the potential high-risk classification of biometric AI features and the significant compliance burden and penalties involved.

Evidence: https://www.orcam.com/en-us/home, https://www.orcam.com/en-us/orcam-myeye-3-pro, https://www.orcam.com/en-us/terms-of-use

CPRA — Partially Compliant

Risk is Medium because: (1) OrCam explicitly addresses CCPA in its Privacy Statement, indicating awareness and partial compliance; (2) OrCam Inc. operates in the US (New York) and sells to California residents, triggering CCPA/CPRA obligations if revenue or data thresholds are met; (3) the Privacy Statement includes California-specific rights (access, deletion, opt-out of sale, non-discrimination, Shine the Light Law) which demonstrates compliance intent; (4) however, the Privacy Statement was last updated in August 2023 and may not fully reflect CPRA amendments effective January 2023 (e.g., sensitive personal information rights, opt-out of sharing for cross-context behavioral advertising, data minimization requirements); (5) OrCam collects sensitive personal information including health data and precise geolocation, which triggers CPRA's enhanced sensitive PI protections; (6) California AG and CPPA enforcement is active, with fines up to $7,500 per intentional violation.

Evidence: https://www.orcam.com/en-us/privacy-statement

Financials

Three-year financials

Financial Resilience Score: 5/10

OrCam Technologies is a private Israeli AI/assistive-tech unicorn co-founded by the Mobileye founders (Amnon Shashua and Ziv Aviram), which lends significant credibility, access to capital, and top-tier talent. The company has raised over US$130 million cumulatively, was valued at approximately US$1 billion in 2019, and has built a differentiated IP portfolio in on-device computer vision and OCR. Its global footprint across ~50 countries and ~25 languages, combined with a defensible niche in assistive medical devices (often reimbursed by insurers/veterans agencies), provides some revenue durability. However, the company faces material challenges. The shelved 2021 Tel Aviv IPO (targeted at US$2–3 billion valuation) and reported ~20% workforce layoffs in 2023 suggest ongoing profitability struggles and a difficult commercial environment. Press-leaked 2020 revenue of ~US$34 million alongside continuing net losses points to a company still burning cash. Competitive pressure from smartphones with built-in accessibility features, smart glasses (Meta/Ray-Ban), and emerging AI wearables (Envision, Humane) threatens OrCam's premium price points (US$2,000–4,500 per device). Additional risks include the lack of public financial transparency, dependence on reimbursement policy in key markets (Germany, US veterans schemes), a relatively narrow addressable market, and geopolitical/operational exposure due to Israel-based R&D and manufacturing during the 2023–2024 conflict period. Overall, resilience is moderate—supported by strong founders and IP, but constrained by unprofitability, competitive threats, and limited financial visibility.

Key strengths: Strong founder pedigree (Mobileye co-founders Shashua and Aviram), Cumulative funding of >US$130 million with Intel Capital among backers, US$1 billion unicorn valuation achieved in 2019, Differentiated proprietary computer-vision and OCR IP portfolio, Global distribution across ~50 countries and ~25 languages, Defensible niche in assistive devices with insurance/reimbursement support, Continued product refresh cadence (MyEye 3 Pro, Read 5 in 2024–2025)

Risk factors: No public financial transparency as a private company, Ongoing cash burn and unprofitability, Shelved 2021 IPO indicating market/valuation challenges, ~20% workforce layoffs reported in 2023, Competitive pressure from smartphones, smart glasses, and AI wearables, Narrow addressable market with high ASP dependence, Reimbursement/policy dependence in key markets, Geopolitical and operational risk from Israel-based operations

Revenue by geography

Revenue by product/service

Workforce by country

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report